Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Ferrex	LSE:FRX	London	Ordinary Share	GB00B649J414	ORD 0.1P

Share Name

Share Symbol

Market

Type

Share ISIN

Share Description

Ferrex

LSE:FRX

London

Ordinary Share

GB00B649J414

ORD 0.1P

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.45

0.00

01:00:00

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Industry Sector

Turnover

Profit

EPS - Basic

PE Ratio

Market Cap

N/A

Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduce

27/08/2009 11:31pm

PR Newswire (US)

Ferrex (LSE:FRX)
Historical Stock Chart

From May 2019 to May 2024

-- Once-a-day tablet Daxas(R) (roflumilast) is a first-in-class treatment under development targeting inflammation, the underlying cause of chronic obstructive pulmonary disease (COPD) ZURICH, Aug. 27 /PRNewswire/ -- Nycomed and Forest Laboratories today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD. COPD is an under-diagnosed progressive lung disease that may lead to death. Worldwide, COPD kills four people every minute and the World Health Organization (WHO) predicts that it will be the third leading cause of death by 2030. WHO estimates that 80 million people have moderate to severe COPD. Roflumilast, a once-a-day oral tablet, would be the first in an entirely new class of treatment for COPD if it receives regulatory approval from the authorities in Europe (EMEA) and the US (FDA). The phase III placebo-controlled trials of roflumilast evaluated the treatment in two 12-month (Lancet 2009; 374: 685-694) and two six-month studies (Lancet 2009; 374: 695-703), involving 4,500 patients in ten countries. Details of the results of the four studies will be published in The Lancet on August 29 (data and information under embargo until Friday, August 28 at 00:01am GMT). The two 12-month studies published in The Lancet demonstrated that roflumilast produced a statistically significant and clinically relevant reduction in exacerbations (lung attacks that need treatment with systemic steroids or lead to hospitalisation), even for patients who were also taking long-acting bronchodilators. The studies showed a reduction in moderate to severe exacerbations by 17 percent per patient per year (rate of 1.14 events per year with roflumilast vs. 1.37 per year with placebo, p

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

FRX Ferrex